Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.

Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome’s website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation.

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260106254447/en/

Investor Contact
Max Rosett
Chief Financial Officer
[email protected]

Source: Immunome, Inc.

You May Also Be Interested In

• ComEd Debuts Mobile Assistance Unit at Waukegan Resource Fair, Bringing On-Site Bill Help Directly to Customers
• Crypto Update Flashes the Bottom Signal and Pepeto Is Where Early Money Is Rushing
• 2026’s Top Window Covering Trends, and the Sister-Owned Store Carrying Them All